Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK4023393A
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK4023393A is an investigational meningococcal ABCWY combination vaccine candidate developed by GSK that is intended to provide broad protection against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in a single product.[6][8] It combines antigenic components from existing MenB and MenACWY vaccines into a next‑generation formulation (MenABCWY-2Gen) and has been evaluated in Phase I/II studies for safety, immunogenicity, and optimal formulation and dosing schedules in adolescents and adults.[6][13] The vaccine elicits serum bactericidal antibodies against all five targeted serogroups and is being developed to simplify immunization regimens and improve coverage compared with separate MenB and MenACWY vaccination.
- Other names
- MenABCWY-2GenMenABCWY2GenMenABCWY 2Gen
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)MenB OMV (Neisseria meningitidis serogroup B outer membrane vesicle)fHbp (Factor H-binding protein)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideNadA (Neisserial adhesin A)NHBA (Neisserial heparin-binding antigen)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on GSK4023393A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK4023393A.